MedTrace Logo

A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas

NCT05566743 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-10-04

No results posted yet for this study

Summary

A randomized phase II study evaluating maintenance therapy after first line induction chemotherapy in metastatic cancer pancreas.

Conditions

  • Cancer of Pancreas

Interventions

DRUG

Capecitabine

maintenance capecitabine after 4 months of FOLFRINOX

OTHER

follow up

follow up after 4 months of FOLFRINOX

Sponsors & Collaborators

  • Menoufia University

    lead OTHER

Principal Investigators

  • Nahla Atef Shabaan, Master · Menoufia University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-11
Primary Completion
2023-09-11
Completion
2024-09-11

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05566743 on ClinicalTrials.gov